Influence of immunosuppression on the prevalence of cancer after kidney transplantation

Marcén, R.; Pascual, Julio; Tato, A; Teruel, J.L.; Villafruela, J.J.; Fernández, Marcelo Sanmartín; Tenorio, María; Burgos, F.J.; Ortuño, J

doi:10.1016/s0041-1345(03)00669-9

Cited by 80 publications

(60 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The ratio we observed was more similar to the French and Spanish populations [21,35]. Differences in the ratio may be explained by differences in factors such as annual sunshine hours, UV index (latitude, degree of pollution, ozone layer integrity), different skin types (genetic background) and outdoor activities [5,20,23,37].…”

Section: Discussionsupporting

confidence: 62%

First and subsequent nonmelanoma skin cancers: incidence and predictors in a population of New Zealand renal transplant recipients

Mackenzie¹,

Wells

Lynn

et al. 2009

Nephrology Dialysis Transplantation

View full text Add to dashboard Cite

Background. Renal transplant recipients (RTRs) have an increased risk of developing nonmelanoma skin cancers (NMSCs). The aims of this study were to determine the incidence and subsequent history of NMSCs in RTRs, together with risk factors. 14.2, 22.9) from transplant, as estimated by survival analysis. Individual predictors of first NMSC in RTRs were older age at first transplant (P < 0.0001), male sex (P = 0.006) and initial immunosuppression regimen (P = 0.001); only age (P < 0.0001) and male gender (P = 0.003) were significant predictors in a joint model. MethodsThe mean rate of subsequent NMSCs was 1.67 per year (95% CI = 1.32, 2.11). Older age at first renal transplant (P = 0.009) or at discovery of the first NMSC (P = 0.01) was associated with a higher annual rate of new NMSC following the discovery of the first NMSC. The median survival time to a second NMSC was 2.2 years (CI 1.4, 3.0). Fourteen patients died of metastatic squamous cell carcinoma (15% case fatality). Conclusions. NMSCs are a major health issue for RTRs, especially in older males. Once RTRs have developed their first NMSC, ongoing surveillance and prompt treatment are essential.

show abstract

Section: Discussionsupporting

confidence: 62%

First and subsequent nonmelanoma skin cancers: incidence and predictors in a population of New Zealand renal transplant recipients

Mackenzie¹,

Wells

Lynn

et al. 2009

Nephrology Dialysis Transplantation

View full text Add to dashboard Cite

show abstract

“…We classified the diagnoses of chronic diseases into the four categories listed in Appendix 2. In addition, we retrieved information on prescriptions redeemed for azathioprine (ATC code: L04AX01) and methotrexate (ATC code: L01BA01), as use of these drugs has been associated with an increased risk of skin cancer (Glover et al, 1997;Jensen et al, 1999;Marcen et al, 2003) and NHL (Kinlen, 1992).…”

Section: Methodsmentioning

confidence: 99%

Use of oral glucocorticoids and risk of skin cancer and non-Hodgkin's lymphoma: a population-based case–control study

et al. 2008

View full text Add to dashboard Cite

In North Jutland County, Denmark, we investigated whether use of oral glucocorticoids was associated with an increased risk of developing basal cell carcinoma (BCC), squamous cell carcinoma (SCC), malignant melanoma (MM), and non-Hodgkin's lymphoma (NHL). From the Danish Cancer Registry we identified 5422 BCC, 935 SCC, 983 MM, and 481 NHL cases during 1989 -2003. Using risk-set sampling we selected four age-and gender-matched population controls for each case from the Civil Registration System. Prescriptions for oral glucocorticoids before diagnosis were obtained from the Prescription Database of North Jutland County on the basis of National Health Service data. We used conditional logistic regression to estimate incidence rate ratios (IRRs), adjusting for chronic medical diseases (information about these were obtained from the National Patient Registry) and use of other immunosuppressants. We found slightly elevated risk estimates for BCC (IRR, 1.15 (95% CI: 1.07 -1.25)), SCC (IRR, 1.14 (95% CI: 0.94 -1.39)), MM (IRR, 1.15 (95% CI: 0.94 -1.41), and NHL (IRR, 1.11 (95% CI: 0.85 -1.46)) among users of oral glucocorticoids. Our study supports an overall association between glucocorticoid use and risk of BCC that cannot be explained by the presence of chronic diseases or concomitant use of other immunosuppressants.

show abstract

“…Sugie et al 32 discovered that cyclosporine interferes with p53 signaling and nucleotide excision repair, which may lead to increased SCC development. Cyclosporine is associated with SCC development in a dose dependent manner, and combination with azathioprine and prednisone is associated with a 3-fold higher risk of skin cancer versus azathioprine and prednisone alone [33][34][35] . Although tacrolimus is a calcineurin inhibitor, the risk of SCC is not as high as with cyclosporine 36 .…”

Section: Discussionmentioning

confidence: 99%

Clinical Findings, Treatments and Outcomes of Transplant Recipients with Metastatic Skin Cancer

2017

ARC Journal of Dermatology

View full text Add to dashboard Cite

Influence of immunosuppression on the prevalence of cancer after kidney transplantation

Cited by 80 publications

References 11 publications

First and subsequent nonmelanoma skin cancers: incidence and predictors in a population of New Zealand renal transplant recipients

First and subsequent nonmelanoma skin cancers: incidence and predictors in a population of New Zealand renal transplant recipients

Use of oral glucocorticoids and risk of skin cancer and non-Hodgkin's lymphoma: a population-based case–control study

Clinical Findings, Treatments and Outcomes of Transplant Recipients with Metastatic Skin Cancer

Contact Info

Product

Resources

About